Neurodiagnostics Symposium
Wednesday, September 23 at 9:00 am
-
5:00 pm
Add to Calendar
2026-09-23 09:00:00
2026-09-23 17:00:00
Neurodiagnostics Symposium
Neurodiagnostics Symposium
Advancing Biomarker Discovery and Application
This in-person event aims to convene the neurosciences community working on biomarker discovery to foster connection, forge collaborations, and provide insights into the process of advancing early candidate biomarkers to clinical use.
Registration for the event has reached capacity. Please contact Lauren de Remer ([email protected]) to be placed on a waitlist. Additionally, please note that walk-ins will not be accommodated.
Program Overview
Registration begins at 8:30am | Coffee and breakfast provided
Morning Sessions | 9:00am–12:10pm
Welcome and Introduction by Bill Seeley and Michael Wilson
Session 1: Biomarker Discovery
"Proteomic Approaches to Understanding Neurobiology"
Danielle Swaney
"Beyond Encephalitis: Recurrent Autoantibody Signals in Psychotic Spectrum Disorders"
Christopher Bartley
"From Biomarker to Causality: Genetic Drug Target Validation in Humans"
Iyas Daghlas
Session 2: Validation Strategies & Targeted Assay Development
"Epitope Discovery and Validation Identify Epstein-Barr Virus Antibody Profiles Linked to Multiple Sclerosis Risk"
Krista McCutcheon
"Discovery to Deployment Pipeline for Soluble Protein Markers"
Ahmed Abdelhak (Including work from collaborator Julio Rojas-Martinez)
"Amyloid Amplification Assays: Past, Present, and Future"
Michael Metrick
Lunch provided from 12:10-1:10pm
Afternoon Sessions | 1:10pm-4:00pm
Session 3: Clinical Implementation
"Clinical Implementation of Novel Biomarkers: You Are Not Trained for This Journey"
Alan Wu
"Does It Work In the Real World? Designing New Biomarker Studies for Generalizability"
Elizabeth Rose Mayeda
Session 4: Scalability & Academic-Industry Partnerships
"Immunectra: The Journey From UCSF Clinical Research to Founding a Venture-Scale Company"
Caroline Vissers
"Neurodiagnostics: The State of the Market From the University Perspective"
David Morris
"It’s Not All Over Until the Patients Benefit: The Case for Founding a Company Around Your Discovery"
Douglas Crawford
Reception | 4-5pm
675 18th Street
Pritzker Building, Auditorium
San Francisco, CA 94107
United States
View on Map
UCSF Weill Institute For Neurosciences
Department Of Neurological Surgery
Department Of Neurology
Department Of Psychiatry And Behavioral Sciences
[email protected]
America/Los_Angeles
public
675 18th Street
Pritzker Building, Auditorium
San Francisco, CA 94107
United States
View on Map
Neurodiagnostics Symposium
Advancing Biomarker Discovery and Application
This in-person event aims to convene the neurosciences community working on biomarker discovery to foster connection, forge collaborations, and provide insights into the process of advancing early candidate biomarkers to clinical use.
Registration for the event has reached capacity. Please contact Lauren de Remer ([email protected]) to be placed on a waitlist. Additionally, please note that walk-ins will not be accommodated.
Program Overview
Registration begins at 8:30am | Coffee and breakfast provided
Morning Sessions | 9:00am–12:10pm
Welcome and Introduction by Bill Seeley and Michael Wilson
Session 1: Biomarker Discovery
"Proteomic Approaches to Understanding Neurobiology"
Danielle Swaney
"Beyond Encephalitis: Recurrent Autoantibody Signals in Psychotic Spectrum Disorders"
Christopher Bartley
"From Biomarker to Causality: Genetic Drug Target Validation in Humans"
Iyas Daghlas
Session 2: Validation Strategies & Targeted Assay Development
"Epitope Discovery and Validation Identify Epstein-Barr Virus Antibody Profiles Linked to Multiple Sclerosis Risk"
Krista McCutcheon
"Discovery to Deployment Pipeline for Soluble Protein Markers"
Ahmed Abdelhak (Including work from collaborator Julio Rojas-Martinez)
"Amyloid Amplification Assays: Past, Present, and Future"
Michael Metrick
Lunch provided from 12:10-1:10pm
Afternoon Sessions | 1:10pm-4:00pm
Session 3: Clinical Implementation
"Clinical Implementation of Novel Biomarkers: You Are Not Trained for This Journey"
Alan Wu
"Does It Work In the Real World? Designing New Biomarker Studies for Generalizability"
Elizabeth Rose Mayeda
Session 4: Scalability & Academic-Industry Partnerships
"Immunectra: The Journey From UCSF Clinical Research to Founding a Venture-Scale Company"
Caroline Vissers
"Neurodiagnostics: The State of the Market From the University Perspective"
David Morris
"It’s Not All Over Until the Patients Benefit: The Case for Founding a Company Around Your Discovery"
Douglas Crawford
Reception | 4-5pm
Discovery
Neuroscience
Translational
Biomarkers
Diagnostics